WO2002016946A3 - ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF IgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES - Google Patents

ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF IgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES Download PDF

Info

Publication number
WO2002016946A3
WO2002016946A3 PCT/US2001/026348 US0126348W WO0216946A3 WO 2002016946 A3 WO2002016946 A3 WO 2002016946A3 US 0126348 W US0126348 W US 0126348W WO 0216946 A3 WO0216946 A3 WO 0216946A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
oral fluid
antibodies
trapping zone
antibody
Prior art date
Application number
PCT/US2001/026348
Other languages
French (fr)
Other versions
WO2002016946A2 (en
Inventor
Jonathan Zmuda
Lance A Liotta
Gordon Whiteley
Original Assignee
Jonathan Zmuda
Lance A Liotta
Gordon Whiteley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonathan Zmuda, Lance A Liotta, Gordon Whiteley filed Critical Jonathan Zmuda
Priority to AU2001286669A priority Critical patent/AU2001286669A1/en
Publication of WO2002016946A2 publication Critical patent/WO2002016946A2/en
Publication of WO2002016946A3 publication Critical patent/WO2002016946A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

A method and device to detect Hepatitis C (HCV) antibodies in oral fluid is provided. This method introduces a non-antibody detection molecule that labels all classes of patient antibodies in oral fluid, followed by the specific concentration of labeled anti-HCV antibodies by selective capture in a trapping zone consisting of peptide antigens derived from the HCV genome. Signal generated by the labeled antibodies present in the trapping zone is proportional to the number of anti-HCV antibodies bound to the antigens present in the trapping zone. Presence of signal derived from the capture of antibody/detection molecule complexes in the trapping zone is indicative of past exposure to HCV. Previous attempts to utilize oral fluid to screen for HCV exposure have been largely unsuccessful, likely due to the vastly decreased levels of antibody present in the oral fluid compared to serum or plasma as well as the inability to detect other classes of anti-HCV than IgG. A method capable of utilizing oral fluid as an alternative to serum or plasma provides many advantages over traditional blood-based analyses. Oral fluid collection is rapid and non-invasive and eliminates the risks of needle exposure. Oral fluid can be collected by non-medical personnel, relieving health care professionals of the time-consuming and economic burden of obtaining serum samples. Furthermore, oral fluid-based assays may prove to be the preferred method of testing for infants, young children and in developing nations, as well as for patient groups where blood collection is difficult, such as intravenous drug users, that constitute a significant portion of total HCV cases.
PCT/US2001/026348 2000-08-23 2001-08-23 ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF IgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES WO2002016946A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001286669A AU2001286669A1 (en) 2000-08-23 2001-08-23 Oral fluid rapid assay for hepatitis c virus (hcv) antibodies using non-antibody labeling of iga molecules recognizing hcv peptide epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22725400P 2000-08-23 2000-08-23
US60/227,254 2000-08-23

Publications (2)

Publication Number Publication Date
WO2002016946A2 WO2002016946A2 (en) 2002-02-28
WO2002016946A3 true WO2002016946A3 (en) 2003-01-16

Family

ID=22852386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026348 WO2002016946A2 (en) 2000-08-23 2001-08-23 ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF IgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES

Country Status (3)

Country Link
US (1) US20020150884A1 (en)
AU (1) AU2001286669A1 (en)
WO (1) WO2002016946A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837939B2 (en) 2003-11-14 2010-11-23 Alere Switzerland Gmbh Rapid sample collection and analysis device and methods of use
US8071394B2 (en) 2006-07-26 2011-12-06 Alere Switzerland Gmbh Test device for detecting an analyte in a liquid sample
US8871155B2 (en) 2005-11-30 2014-10-28 Alere Switzerland Gmbh Devices for detecting analytes in fluid sample

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7114403B2 (en) * 2003-05-30 2006-10-03 Oakville Hong Kong Co., Ltd Fluid collection and application device and methods of use of same
WO2005008216A2 (en) * 2003-07-11 2005-01-27 Oakville Hong Kong Co., Limited Sanitary fluid collection, application and storage device and methods of use of same
WO2011152793A1 (en) * 2010-06-02 2011-12-08 Mp Biomedicals Asia Pacific Pte Ltd Rapid multi-line hepatitis c virus assay
CA3205763A1 (en) * 2011-11-28 2013-06-06 Immunoprofile, Llc Point of care immunization testing system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792605A (en) * 1996-07-05 1998-08-11 Ochnio; Jan J. Assay for Hepatitis A virus specific antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792605A (en) * 1996-07-05 1998-08-11 Ochnio; Jan J. Assay for Hepatitis A virus specific antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELSANA S ET AL.: "HCV antibodies in saliva and urine.", J. MED. VIROL., vol. 55, 1998, pages 24 - 27, XP002215072 *
TALIANI G ET AL.: "Hepatitis C virus infection of salivary gland epithelial cells.", J. HEPATOL., vol. 26, 1997, pages 1200 - 1206, XP002215073 *
VAN DOORNUM GJJ ET AL.: "Evaluation of hepatitis C antibody testing in saliva specimens collected by two different systems in comparison with HCV antibody and HCV RNA in serum.", J. MED. VIROL., vol. 64, 2001, pages 13 - 20, XP002215074 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837939B2 (en) 2003-11-14 2010-11-23 Alere Switzerland Gmbh Rapid sample collection and analysis device and methods of use
US8871155B2 (en) 2005-11-30 2014-10-28 Alere Switzerland Gmbh Devices for detecting analytes in fluid sample
US8071394B2 (en) 2006-07-26 2011-12-06 Alere Switzerland Gmbh Test device for detecting an analyte in a liquid sample

Also Published As

Publication number Publication date
AU2001286669A1 (en) 2002-03-04
US20020150884A1 (en) 2002-10-17
WO2002016946A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
Wright et al. Hepatitis C virus not found in fulminant non-A, non-B hepatitis
Quiroga et al. IgM antibody to hepatitis C virus in acute and chronic hepatitis C
Bradley et al. Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus
Ryu et al. Development of a rapid automated fluorescent lateral flow immunoassay to detect hepatitis B surface antigen (HBsAg), antibody to HBsAg, and antibody to hepatitis C
CN107666961A (en) blood analysis system and method
Fenollar et al. Diagnosis of rickettsial diseases using samples dried on blotting paper
DE69131707D1 (en) Detection of hepatitis C using recombinant antigens
WO2002016946A3 (en) ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF IgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES
Tagliabue et al. A label-free immunoassay for Flavivirus detection by the Reflective Phantom Interface technology
Hsu et al. Antibodies to hepatitis C virus in low-risk blood donors: implications for counseling positive donors
Moe et al. Diagnosis of Norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant Norwalk virus antigen
Botte et al. Epidemiology of HCV infection in the general population and in blood transfusion
US8765386B2 (en) Oral fluid rapid assay for hepatitis C virus (HCV) antibodies using non-antibody labeling of IgA molecules recognizing HCV peptide epitopes
Zmuda et al. Recognition of multiple classes of hepatitis C antibodies increases detection sensitivity in oral fluid
Montebugnoli et al. A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood
EP1882943A1 (en) Saliva immunochromatographic detection cup
Fisker et al. Low hepatitis B prevalence among pre‐school children in Denmark: Saliva anti‐HBc screening in day care centres
Shrestha et al. Occult hepatitis B infection in end-stage renal disease patients starting maintenance hemodialysis at a tertiary care hospital: a descriptive cross-sectional study
Srithanaviboonchai et al. Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals
Mao et al. Detection of SARS-CoV-2 Antibodies in Oral Fluid Using a Magnetic Particle-Based Chemiluminescence Immunoassay—Beijing Municipality, China, 2021
Gautier et al. Evaluation of three commercialized rapid point-of-care tests for detection of anti-hepatitis C virus antibodies in Burkina Faso
CN108982838A (en) A kind of protein chip and preparation method thereof for infectious disease detection
Lin et al. Seroprevalence of hepatitis C virus infection and its association with natural infection of hepatitis B virus among preschool children in Taiwan
Neville The extent of genotype-specific humoral immunity produced on infection with hepatitis C virus: relevance for serological screening and diagnosis
Pinsky et al. Comparison of fingerstick versus venipuncture for antibody testing of measles and rubella

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP